Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of "Moderate Buy" by Analysts

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have been given an average rating of "Moderate Buy" by the five research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $9.00.

Several analysts have issued reports on the company. Royal Bank of Canada restated an "outperform" rating and issued a $8.00 price objective on shares of Pyxis Oncology in a research note on Wednesday, March 19th. HC Wainwright reiterated a "buy" rating and issued a $5.00 price objective on shares of Pyxis Oncology in a report on Monday, May 19th.

Pyxis Oncology Stock Performance

NASDAQ PYXS traded down $0.01 during trading hours on Thursday, hitting $1.22. 101,802 shares of the company traded hands, compared to its average volume of 739,420. The business's 50-day moving average is $1.06 and its 200-day moving average is $1.50. The stock has a market capitalization of $75.33 million, a price-to-earnings ratio of -1.19 and a beta of 1.15. Pyxis Oncology has a twelve month low of $0.83 and a twelve month high of $5.39.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.06). Analysts predict that Pyxis Oncology will post -1.04 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in PYXS. ProShare Advisors LLC acquired a new position in Pyxis Oncology in the 4th quarter valued at $26,000. Ameriprise Financial Inc. bought a new position in shares of Pyxis Oncology in the 4th quarter valued at $35,000. Caption Management LLC bought a new position in shares of Pyxis Oncology in the 4th quarter valued at $35,000. Commonwealth Equity Services LLC raised its holdings in shares of Pyxis Oncology by 61.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company's stock worth $41,000 after buying an additional 10,000 shares in the last quarter. Finally, Graham Capital Management L.P. bought a new stake in shares of Pyxis Oncology during the 4th quarter worth $47,000. Institutional investors and hedge funds own 39.09% of the company's stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.